488 related articles for article (PubMed ID: 30406152)
21. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of colorectal cancer: new perspectives after a long path.
Correale P; Botta C; Ciliberto D; Pastina P; Ingargiola R; Zappavigna S; Tassone P; Pirtoli L; Caraglia M; Tagliaferri P
Immunotherapy; 2016 Nov; 8(11):1281-1292. PubMed ID: 27993089
[TBL] [Abstract][Full Text] [Related]
23. Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future.
Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2018 Jul; 27(7):569-572. PubMed ID: 29958097
[TBL] [Abstract][Full Text] [Related]
24. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.
Kean LS; Turka LA; Blazar BR
Immunol Rev; 2017 Mar; 276(1):192-212. PubMed ID: 28258702
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
[TBL] [Abstract][Full Text] [Related]
26. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
Lucca LE; Hafler DA
Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
[TBL] [Abstract][Full Text] [Related]
27. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
29. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
Koster BD; de Gruijl TD; van den Eertwegh AJ
Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment.
Cappelli LC; Naidoo J; Bingham CO; Shah AA
Immunotherapy; 2017 Jan; 9(1):5-8. PubMed ID: 28000525
[No Abstract] [Full Text] [Related]
31. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
32. Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.
Sanchez-Correa B; Lopez-Sejas N; Duran E; Labella F; Alonso C; Solana R; Tarazona R
Cancer Immunol Immunother; 2019 May; 68(5):861-870. PubMed ID: 30953117
[TBL] [Abstract][Full Text] [Related]
33. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.
Sharabi AB; Lim M; DeWeese TL; Drake CG
Lancet Oncol; 2015 Oct; 16(13):e498-509. PubMed ID: 26433823
[TBL] [Abstract][Full Text] [Related]
34. Innovation in Bladder Cancer Immunotherapy.
Grossman HB; Lamm DL; Kamat AM; Keefe S; Taylor JA; Ingersoll MA
J Immunother; 2016 Oct; 39(8):291-7. PubMed ID: 27428265
[TBL] [Abstract][Full Text] [Related]
35. Combinatorial Cancer Immunotherapies.
Hellmann MD; Friedman CF; Wolchok JD
Adv Immunol; 2016; 130():251-77. PubMed ID: 26923003
[TBL] [Abstract][Full Text] [Related]
36. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
Qi J; Jin F; Xu X; Du Y
Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
[TBL] [Abstract][Full Text] [Related]
37. T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.
Mirzaei R; Sarkar S; Yong VW
Trends Immunol; 2017 Feb; 38(2):104-115. PubMed ID: 27964820
[TBL] [Abstract][Full Text] [Related]
38. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more.
Chiossone L; Vienne M; Kerdiles YM; Vivier E
Semin Immunol; 2017 Jun; 31():55-63. PubMed ID: 28943093
[TBL] [Abstract][Full Text] [Related]
39. Delivery Strategies for Immune Checkpoint Blockade.
Chen Q; Wang C; Chen G; Hu Q; Gu Z
Adv Healthc Mater; 2018 Oct; 7(20):e1800424. PubMed ID: 29978565
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
